BioTuesdays

FDA clears Eikon IND for Phase 1/2 study of EIK1006 in prostate cancer

Eikon Therapeutics Logo

Eikon Therapeutics (NASDAQ: EIKN) has announced FDA clearance of its Investigational New Drug (IND) application for EIK1006, a novel androgen receptor antagonist, paving the way for its first-in-human Phase 1/2 study in patients with advanced metastatic prostate cancer.

According to Eikon, the company plans to initiate the Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen-pathway-modulation-resistant prostate cancer (mAPMRPC) whose disease has progressed despite established anti-hormonal therapy. Formerly known as metastatic castration-resistant prostate cancer (mCRPC), mAPMRPC remains an area of high unmet need, as resistance to established anti-hormonal therapy is common and limits durable benefit.

In a statement, Roy Baynes, MD, PhD, chief medical officer of Eikon, commented, “IND clearance for EIK1006 is an important milestone for Eikon and for patients with advanced metastatic prostate cancer, where resistance to current androgen receptor-directed therapies remains a significant challenge. EIK1006’s progression into the clinic reflects the strength of our proprietary drug discovery platform and our ability to nominate novel chemical material and rapidly advance them into human studies. We look forward to initiating clinical evaluation of EIK1006 and to continuing to translate our platform into potential new medicines for patients with significant unmet need.”

POWERED BY

Stay Ahead in Healthcare & Life Sciences